Immune cells enlisted to fight hard-to-treat ovarian cancer

This early-phase study tested a new treatment for women with ovarian, fallopian tube, or peritoneal cancer that came back or didn't respond to standard chemotherapy. The approach involved taking a type of white blood cell (monocytes) from each participant, activating them with two immune-boosting drugs (Sylatron and Actimmune), and infusing them back into the abdomen. The goal was to see if this combination was safe and could slow tumor growth. The study was terminated early, so results are limited.